LeonaBio, Inc.
LONANASDAQHealthcareBiotechnology
Latest quote
$7.73
+$0.045 · +0.59%
After-hours
$7.73
$0.00 · 0.00%
Aug 24, 4:10 PM ET
LONA company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Hold
Wait — insufficient conviction to act
Valuation
45
Fair Value
Momentum
72
Gaining
Sentiment
63
Bullish
Risk resilience
34
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteLeonaBio, Inc. operates as a biopharmaceutical firm engaged in clinical-stage development. Its core mission revolves around crafting small molecule therapies aimed at revitalizing neurological function and arresting the advancement of neurodegenerative conditions. The company's active development portfolio encompasses ATH-1105, an experimental therapy for amyotrophic lateral sclerosis (ALS) that is currently undergoing Phase 1 clinical assessment. Similarly, ATH-1020 is also in Phase 1 trials, targeting various neurodegenerative disorders. Furthermore, LeonaBio has an array of earlier-stage compounds in preclinical research. The company, which was originally established as Athira Pharma, Inc., rebranded itself as LeonaBio, Inc. in January 2026. Founded in 2011, its corporate headquarters are situated in Bothell, Washington.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Mark J. Litton
- Listed since
- Sep 18, 2020
- Employees
- 19
Market position
Day range
Current $7.73
52-week range
Current $7.73
- Open
- $7.57
- Previous close
- $7.685
- Volume
- 8.29K
- 0.22× average
- Average volume
- 38.43K
- Average daily volume
- Market cap
- 30.49M USD
- Beta
- 2.04
- Market reference 1
- 50-day average
- $6.75
- +14.52% above average
- 200-day average
- $6.75
- +14.52% above average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- -36.11M USD
- P/E (TTM)
- -0.24×
- P/B (TTM)
- 0.98×
- P/S (TTM)
- 0×
- EV / EBITDA
- 1.09×
- Earnings yield
- -326.28%
- Free cash flow yield
- -141.28%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 0.00%
- Operating margin
- 0.00%
- Net margin
- 0.00%
- Return on equity
- -380.03%
- Return on assets
- -114.60%
- Return on invested capital
- -226.69%
Financial health
- Debt / equity
- 0.02×
- Current ratio
- 1.88×
- Altman Z-score
- -15.25
- Piotroski F-score
- 1 of 9
Financial statements
Income trends
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 68.09M USD | — | — | — | 479K USD |
| Gross profit | −68.09M USD | — | — | — | −479K USD |
| Research and development | 17.5M USD | 70.68M USD | 93.79M USD | 61.46M USD | 42.79M USD |
| Selling, general, and administrative | 16.68M USD | 26.09M USD | 33.3M USD | 32.55M USD | 21.23M USD |
| Operating expenses | 34.18M USD | 100.9M USD | 125.47M USD | 104.02M USD | 63.54M USD |
| Interest income | — | 3.96M USD | 7.64M USD | 3.22M USD | 337K USD |
| Interest expense | — | — | — | 24.32M USD | 3K USD |
| Depreciation and amortization | 972K USD | 970K USD | 969K USD | 845K USD | 479K USD |
| Operating income | −102.27M USD | −100.9M USD | −125.47M USD | −104.02M USD | −64.02M USD |
| Net income | −105.61M USD | −96.94M USD | −117.67M USD | −95.64M USD | −54.85M USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 18%
- 2 beats, 8 misses, 1 met estimate
- Average EPS surprise
- -468.90%
- 11 comparable reports
- Latest EPS result
- -0.8
- Estimate -1.39 · Beat by 42.40%
EPS: actual versus estimate
Recent quarterly results
LONA news
Corporate actions
Corporate action history
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Sep 18, 2025 | 1:10 | — | — |
Effective Sep 18, 2025
1:10
LONA peers
ETFs holding LONA
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI1.29M0.00%2.3T USD0.03%$377.07-0.31%
Simplify Propel Opportunities ETFSURI1.15M1.35%85.05M USD2.82%$19.97+0.76%
Vanguard Extended Market ETFVXF581.67K0.00%93.7B USD0.05%$243.43-0.86%
iShares Micro-Cap ETFIWC184.08K0.01%1.53B USD0.60%$196.57-0.79%
U.S. Micro Cap Portfolio ETFDFMC28.46K0.00%8.06B USD0.43%$60.60-0.62%
Dimensional - US Core Equity 1 ETFDCOR20.09K0.00%3.51B USD0.14%$84.35-0.22%
Dimensional - US Core Equity 2 ETFDFAC8.05K0.00%49.31B USD0.17%$45.47-0.31%
Dimensional - US Sustainability Core 1 ETFDFSU2.54K0.00%2.35B USD0.15%$48.200.00%Vanguard Morningstar Total Stock Market ETFVTI- Market value
- 1.29M
- Weight
- 0.00%
- AUM
- 2.3T USD
- Expense ratio
- 0.03%
- Price / 1D
- $377.07-0.31%
Simplify Propel Opportunities ETFSURI- Market value
- 1.15M
- Weight
- 1.35%
- AUM
- 85.05M USD
- Expense ratio
- 2.82%
- Price / 1D
- $19.97+0.76%
Vanguard Extended Market ETFVXF- Market value
- 581.67K
- Weight
- 0.00%
- AUM
- 93.7B USD
- Expense ratio
- 0.05%
- Price / 1D
- $243.43-0.86%
iShares Micro-Cap ETFIWC- Market value
- 184.08K
- Weight
- 0.01%
- AUM
- 1.53B USD
- Expense ratio
- 0.60%
- Price / 1D
- $196.57-0.79%
U.S. Micro Cap Portfolio ETFDFMC- Market value
- 28.46K
- Weight
- 0.00%
- AUM
- 8.06B USD
- Expense ratio
- 0.43%
- Price / 1D
- $60.60-0.62%
Dimensional - US Core Equity 1 ETFDCOR- Market value
- 20.09K
- Weight
- 0.00%
- AUM
- 3.51B USD
- Expense ratio
- 0.14%
- Price / 1D
- $84.35-0.22%
Dimensional - US Core Equity 2 ETFDFAC- Market value
- 8.05K
- Weight
- 0.00%
- AUM
- 49.31B USD
- Expense ratio
- 0.17%
- Price / 1D
- $45.47-0.31%
Dimensional - US Sustainability Core 1 ETFDFSU- Market value
- 2.54K
- Weight
- 0.00%
- AUM
- 2.35B USD
- Expense ratio
- 0.15%
- Price / 1D
- $48.200.00%
Continue in GoAI
Research LONAresearch.disclaimer